Implementing the BioFire FilmArray Pneumonia Panel

Thursday, August 8, 11:30 – 12:30 p.m.
Exhibit Hall, Theater 2
Supported by BioFire Diagnostics


Bacterial culture from lower respiratory tract specimens is the traditional method of pathogen identification for pneumonia patients. Molecular diagnostics offer increased sensitivity and reduced turnaround time compared to culture, but questions remain about their practical implementation for routine use. The BioFire Pneumonia Panel, a multiplex polymerase chain reaction panel that identifies 33 targets in Sputum (including endotracheal aspirates) and bronchoalveolar lavage (BAL) (including mini-BAL), is FDA-cleared and commercially available. Dr. Buchan will discuss his evaluation of the panel as well as plans for clinical implementation.


After attending this session, participants will be able to:

  • Describe the analytical performance of the BioFire Pneumonia Panel.
  • Understand the clinical utility of the BioFire Pneumonia Panel.
  • Provide input into the implementation of the Pneumonia Panel at their institutions.


Blake Buchan, PhD
Assistant Professor of Pathology
Associate Director, Clinical Microbiology
Medical College of Wisconsin